Skip to main content

CellaVision Global Test 2023:2 - Acute Promyelocytic Leukemia (APL)

Case Description

39-year-old man was seen in the emergency room with a 2-week history of:

  • Progressive weakness
  • Fatigue
  • Dizziness
  • Tiny red spots on the arms and legs
  • Widespread bruising
  • Bleeding from the gums

 

Laboratory Findings

Test Result Reference Interval Unit
WBC 2.3 4.5-11.5 x109/L
HGB 11.1 14-17.5 g/dL
HCT 33.1 40-54 %
MCV 90.7 80-100 fL
RDW 16.2 11.5-15 %
PLT 7 150-450 x109/L
Retic 3.0 0.5-2.5 %
PT 33 11-13.5 Seconds
PTT 41 25-35 Seconds
Fibrinogen 88 200-400 mg/dL
D-Dinner > 19,000 < 250 ng/mL

Sample of cells classified in the Global Test 2023:2

Sample of cells classified in the Global test 2023:2

Case Conclusion

The peripheral blood film is suspicious for acute promyelocytic leukemia (APL). Numerous abnormal promyelocytes are present with variable nuclear size and shape; and basophilic cytoplasm with granules that vary in number. Auer rods (often multiple) are visible in roughly 1/3 of the promyelocytes. Several blasts are also noted, however differentiating between blasts and promyelocytes can be challenging. This distinction is not clinically relevant in APL as blasts and promyelocytes are counted together in the WHO classification. Schistocytes are also present, as they are in some APL patients with associated coagulopathy.

     

    Global Test 2023:2 Results Webinar

     

     

    Questions discussed during the webinar include:

    • Why are suspected cases of APL considered medical emergencies?
    • Typical clinical and laboratory findings in APL and differences observed in this case.
    • Genetic abnormalities that cause APL
    • Diagnostic criteria of APL and definition of “blast equivalent.”
    • Guidelines for reporting promyelocytes in the WBC differential
    • Effect of APL treatment on cell morphology
    • APL related coagulopathy